کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4000261 | 1259372 | 2012 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
An update on targeted therapy in metastatic renal cell carcinoma
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 30, Issue 3, May–June 2012, Pages 240–246
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 30, Issue 3, May–June 2012, Pages 240–246
نویسندگان
Giuseppe Lombardi, Fable Zustovich, Martin Donach, Maurizia Dalla Palma, Ornella Nicoletto, Davide Pastorelli,